298 related articles for article (PubMed ID: 17440059)
61. Cyclooxygenase as a target in lung cancer.
Brown JR; DuBois RN
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4266s-4269s. PubMed ID: 15217972
[TBL] [Abstract][Full Text] [Related]
62. CI-988 inhibits growth of small cell lung cancer cells.
Moody TW; Jensen RT
J Pharmacol Exp Ther; 2001 Dec; 299(3):1154-60. PubMed ID: 11714907
[TBL] [Abstract][Full Text] [Related]
63. Tumorigenicity, invasion and metastasis of the small cell lung cancer cell line NCI-H69 and two derivative lines MOG-H69V and MOG-H69VZ.
Khan MZ; McNicol AM; Freshney RI
Anticancer Res; 1996; 16(4A):1659-69. PubMed ID: 8712684
[TBL] [Abstract][Full Text] [Related]
64. Targeting angiogenesis in lung cancer.
Sandler AB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
[TBL] [Abstract][Full Text] [Related]
65. Aromatase inhibitors in human lung cancer therapy.
Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ
Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134
[TBL] [Abstract][Full Text] [Related]
66. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.
Gentile A; Lazzari L; Benvenuti S; Trusolino L; Comoglio PM
Cancer Res; 2011 Apr; 71(8):3132-41. PubMed ID: 21487037
[TBL] [Abstract][Full Text] [Related]
67. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
68. [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
Swidzińska E; Naumnik W; Chyczewska E
Pneumonol Alergol Pol; 2006; 74(4):414-20. PubMed ID: 17427152
[No Abstract] [Full Text] [Related]
69. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
Gilbert JA; Frederick LM; Ames MM
Clin Cancer Res; 2000 Nov; 6(11):4365-72. PubMed ID: 11106255
[TBL] [Abstract][Full Text] [Related]
70. A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes.
Aoki M; Saikawa Y; Hosokawa S; Fukuda K; Kumai K; Kubota T; Yoshida M; Otani Y; Kitajima M
Anticancer Res; 2005; 25(6B):3791-8. PubMed ID: 16309165
[TBL] [Abstract][Full Text] [Related]
71. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
72. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
73. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins.
Dienst A; Grunow A; Unruh M; Rabausch B; Nör JE; Fries JW; Gottstein C
J Natl Cancer Inst; 2005 May; 97(10):733-47. PubMed ID: 15900043
[TBL] [Abstract][Full Text] [Related]
74. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.
Klotz M; Schmid E; Steiner-Hahn K; Rose T; Laube J; Roese L; Henderson D; Krahn T; von Ahsen O
Biomarkers; 2012 Jun; 17(4):325-35. PubMed ID: 22452362
[TBL] [Abstract][Full Text] [Related]
75. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Baguley BC
Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
[TBL] [Abstract][Full Text] [Related]
76. Marine sponge-derived polymeric alkylpyridinium salts as a novel tumor chemotherapeutic targeting the cholinergic system in lung tumors.
Paleari L; Trombino S; Falugi C; Gallus L; Carlone S; Angelini C; Sepcic K; Turk T; Faimali M; Noonan DM; Albini A
Int J Oncol; 2006 Dec; 29(6):1381-8. PubMed ID: 17088975
[TBL] [Abstract][Full Text] [Related]
77. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
Cutz JC; Guan J; Bayani J; Yoshimoto M; Xue H; Sutcliffe M; English J; Flint J; LeRiche J; Yee J; Squire JA; Gout PW; Lam S; Wang YZ
Clin Cancer Res; 2006 Jul; 12(13):4043-54. PubMed ID: 16818704
[TBL] [Abstract][Full Text] [Related]
78. Targeting the Met pathway in lung cancer.
Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
[TBL] [Abstract][Full Text] [Related]
79. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
80. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.
Bu R; Uddin S; Ahmed M; Hussain AR; Alsobhi S; Amin T; Al-Nuaim A; Al-Dayel F; Abubaker J; Bavi P; Al-Kuraya KS
Mol Med; 2012 Mar; 18(1):167-77. PubMed ID: 22113498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
